SGLT2 Inhibitors in Pediatric Heart Failure
SGLT2 inhibitors, particularly dapagliflozin, can be cautiously used in children with heart failure based on emerging evidence, though they are not yet included in established pediatric heart failure guidelines and remain off-label in this population.
Current Guideline Status
The most recent Canadian Cardiovascular Society pediatric heart failure guidelines from 2013 1 do not mention SGLT2 inhibitors, as these agents had not yet been established for heart failure treatment at that time. These guidelines focus on traditional therapies including loop diuretics, ACE inhibitors, beta-blockers, and inotropes. This represents a critical gap, as no major pediatric heart failure guideline currently provides formal recommendations for SGLT2 inhibitor use in children.
Emerging Pediatric Evidence
Efficacy Data
The most recent and highest-quality pediatric study is a 2025 observational trial of dapagliflozin in 49 children with heart failure 2. This study demonstrated significant improvements in left ventricular ejection fraction (increasing from 35% to 40%, p=0.02) and functional class, with a trend toward reduced NT-ProBNP levels (2606 to 1110 pg/ml, p=0.07) at 6 months. The mortality rate was 18%, and 34% experienced the composite outcome of worsening heart failure, transplantation, or death.
A 2025 systematic review 3 corroborated these findings, reporting:
- Increased ejection fractions
- Decreased natriuretic peptide levels
- Improved ventricular dilation and atrioventricular valve regurgitation on echocardiography
Patient Selection Criteria
Based on the available pediatric data 2:
Eligible patients:
- Age: Primarily studied in children 6-15 years (median 11 years)
- Diagnosis: Dilated cardiomyopathy (47%) and congenital heart disease (37%)
- Already on maximized background therapy:
- 96% on RAAS inhibitors
- 92% on mineralocorticoid receptor antagonists
- 78% on beta-blockers
Key principle: SGLT2 inhibitors should be added to goal-directed medical therapy, not used as monotherapy or early in the treatment algorithm.
Recommended Agent and Dosing
Dapagliflozin is the most studied SGLT2 inhibitor in pediatric heart failure 3, 2. While specific pediatric dosing is not formally established, adult heart failure trials used 10 mg daily 4. Pediatric studies have used weight-based or age-appropriate dosing, though exact protocols vary and should be determined in consultation with pediatric cardiology.
Safety Profile and Monitoring
Documented Adverse Events
The pediatric safety profile shows important differences from adults 3, 2:
Renal effects (most concerning):
- Decreased glomerular filtration rate
- Increased serum creatinine
- Elevated risk of acute kidney injury
Other adverse events:
- Genital candidiasis (documented in 4 children) 2
- Sterile pyuria
- Urinary tract infections 3
- Protein-losing enteropathy 3
- Persistent abdominal pain 3
Notably absent: No cases of hypotension, anaphylaxis, or major hemodynamic instability were reported 2.
Monitoring Protocol
Before initiation:
- Baseline renal function (creatinine, eGFR)
- Electrolytes
- Volume status assessment
- Liver function tests
- Blood glucose (even in non-diabetics)
During treatment:
- Renal function monitoring at 2-4 weeks, then every 3 months
- Electrolytes regularly
- Watch for genitourinary symptoms
- Monitor for abdominal pain
- Assess volume status and blood pressure
- Serial echocardiography and NT-ProBNP levels
Critical Caveats and Clinical Approach
The Evidence Gap
The fundamental limitation is that all pediatric data comes from small observational studies and case series—no randomized controlled trials exist in children. The 2013 pediatric guidelines 1 predate SGLT2 inhibitor use in heart failure entirely, while adult guidelines 4 strongly support in-hospital initiation but do not address pediatric populations.
When to Consider Use
SGLT2 inhibitors should be considered in pediatric heart failure when:
- The child has symptomatic heart failure despite optimized conventional therapy (RAAS inhibitor, beta-blocker, MRA)
- Renal function is adequate (specific thresholds not established, but monitor closely)
- The family understands this is off-label use with limited pediatric data
- Close monitoring can be ensured
- Pediatric cardiology is involved in decision-making
When to Avoid or Discontinue
Absolute caution or avoidance:
- Significant baseline renal impairment
- Recurrent urinary tract infections
- Volume depletion or hypotension
- Acute kidney injury
- Type 1 diabetes (risk of euglycemic ketoacidosis, though not specifically reported in pediatric heart failure studies)
Consider discontinuation if:
- Acute kidney injury develops
- Recurrent genitourinary infections occur despite treatment
- Persistent abdominal pain or protein-losing enteropathy develops
- No clinical benefit after 3-6 months
Practical Implementation
Unlike adult heart failure where in-hospital initiation is increasingly standard 4, pediatric initiation should occur in consultation with pediatric cardiology, with careful outpatient follow-up established before discharge if started during hospitalization. The adult data showing rapid benefit within days to weeks 4 suggests potential for in-hospital initiation, but the higher rate of renal complications in children 3 argues for more cautious, monitored initiation.
The decision to use SGLT2 inhibitors in pediatric heart failure represents a calculated risk-benefit analysis: weighing the demonstrated improvements in ejection fraction and symptoms 2 against the concerning renal safety signals 3 in a population where long-term data is absent and guideline support is nonexistent.